SNFGE SNFGE
 
Thématique :
- Foie
Originalité :
Intermédiaire
Solidité :
Intermédiaire
Doit faire évoluer notre pratique :
Dans certains cas
 
 
Nom du veilleur :
Professeur Christine SILVAIN
Coup de coeur :
 
 
Hepatology
  2016/03  
 
  2016 Mar;63(3):703-11  
  doi: 10.1002/hep.28375  
 
  Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.  
 
  Spradling PR, Bulkow LR, Negus SE, Homan C, Bruce MG, McMahon BJ  
  http://www.ncbi.nlm.nih.gov/pubmed/26637987  
 
 

The effect of passively transferred maternal antibody to hepatitis A virus (anti-HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childhood is unclear. We obtained levels of anti-HAV at intervals through age 15-16 years among three groups of Alaskan Native children who initiated a two-dose inactivated hepatitis A vaccination series at ages 6 months (group 1), 12 months (group 2), and 15 months (group 3), each group randomized according to maternal anti-HAV status. Seropositivity (anti-HAV ≥20 mIU/mL) 30 years after the second vaccine dose among the three groups was predicted using a random effects model. One hundred eighty-three children participated in the study; follow-up did not differ significantly by vaccine group or maternal anti-HAV status. Although the frequency of seropositivity among all participants through age 10 years was high (100% among groups 2 and 3 and >90% among group 1), there was a decrease thereafter through age 15-16 years among group 1 children, who initiated vaccination at age 6 months (50%-75%), and among maternal anti-HAV-positive children in groups 2 and 3 (67%-87%), who initiated vaccination at ages 12 months and 15 months, respectively. Nonetheless, the model indicated that anti-HAV seropositivity should persist for ≥30 years after vaccination in 64% of all participants; among those seropositive at age 15-16 years, 84% were predicted to remain so for ≥30 years.

CONCLUSION:

Most children vaccinated during early childhood available for sampling maintained seropositivity through age 15-16 years; however, seropositivity was less frequent among those starting vaccination at age 6 months and among maternal antibody-positive participants who started vaccination at age 12 months or 15 months; overall, our findings support current vaccine recommendations and continued follow-up of this cohort. (Hepatology 2016;63:703-711).

 
Question posée
 
Persistance des ac VHA après vaccination chez l’enfant en fonction de l’âge de la vaccination et de la présence d’ac maternels.
 
Question posée
 
Bonne couverture vaccinale jusqu’au moins l’adolescence mais présence d’ac moins fréquente lorsque la vaccination est effectuée à 6 mois et en présence d’ac maternels d’où la nécessité de maintenir une évaluation de la vaccination à l’âge adulte.
 
Commentaires

Vérifier carnet de vaccination en France et suivre les recommandations  de vaccination même pour le VHA.

 
www.snfge.org